New formulation contains local anesthetic lidocaine for a more comfortable patient experience
Allergan (NYSE: AGN), the maker of BOTOX® (Botulinum Toxin Type A) and the JUVÉDERM™ family of dermal fillers, today announced the launch and availability of its next-generation hyaluronic acid (HA) dermal filler formulation, JUVÉDERM™ XC in India. JUVÉDERM™ XC, which stands for “Extra Comfort”, contains the local anesthetic lidocaine to provide patients with enhanced comfort during treatment.
Approved by the U.S. Food and Drug Administration (FDA) in January 2010, JUVÉDERM™ XC is the first and only smooth-consistency HA dermal filler formulated with lidocaine to smooth the “parentheses” – facial wrinkles around the nose and mouth – for up to one year with just one treatment. JUVEDERM™ currently holds the No. 1 position in the worldwide facial filler market.1
The latest advancement in HA dermal filler, JUVÉDERM™ XC, was launched in the presence of India’s respected aesthetic physicians Dr. Jamuna Pai, Dr. Rashmi Shetty, Dr. Shrilata Suresh Trasi, Dr. Narmada Matang and Dr. Swati Srivastav and vivacious Bollywood actress Yana Gupta.
Dr. Jamuna Pai, Cosmetologist, BLUSH, said “As a physician, my priority is to ensure the best outcomes for my patients, as well as their comfort level during the injection. Previously it often took up to 30 minutes for an anesthetic block to take effect and an almost similar amount of time to reassure the patient. Now, with JUVÉDERM™ XC, patients can enjoy a more comfortable injection experience and possibly less time in the clinic. Its formulation with 0.3% preservative-free lidocaine numbs the treatment area within seconds, potentially reducing the need for an additional anesthetic. Patients can receive the same smooth, long-lasting and natural-looking results demonstrated with existing formulations of JUVEDERM™.”
While launching the new product, Yana Gupta added “Today, feeling good is about looking good. Having charming looks is bliss but maintaining them, in the long run, calls for a lot of effort. Thanks to revolutionary products such as JUVÉDERM™ XC, people have better options to restore their youthful looks in a more relaxed and comforting manner.”
The key ingredient in JUVÉDERM XC dermal filler with lidocaine is hyaluronic acid, a naturally occurring biodegradable complex sugar found in the human body and in mammals. Among other things, hyaluronic acid hydrates the skin and adds volume, contributing to the overall appearance of the skin. The ability of cells to produce hyaluronic acid diminishes with age, often resulting in the formation of facial wrinkles and folds as the skin loses volume. JUVÉDERM® XC is administered in small doses by intradermal injection directly into facial wrinkles and folds, temporarily filling and augmenting the treated area.
Mr. Raghu Kumar, Managing Director, Allergan India, said “The launch of JUVÉDERM™ XC reflects not only our global leadership in medical aesthetics by extending our next-generation dermal filler portfolio to physicians but also our commitment towards patients in India, providing them with a comfortable experience. Our scientific advancements and innovation remain focused on addressing evolving physician and patient needs, ensuring optimal treatment results and high patient satisfaction.”
Allergan is introducing JUVÉDERM™ XC in India via a series of comprehensive, hands-on training sessions for physicians. JUVÉDERM™ XC will be available as physician-administered medical aesthetic treatment in leading aesthetic clinics across India.
About the JUVÉDERM™ family of products:
Allergan's JUVÉDERM ™ dermal filler product line includes JUVÉDERM™ Ultra, JUVÉDERM™ Ultra Plus, JUVÉDERM™ VOLUMA™ and now, JUVÉDERM™ XC , in India, providing physicians with the flexibility to tailor each treatment to the particular needs of the patient with greater comfort.